HIV Infection
640
21
34
489
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
126 trials with published results (20%)
Research Maturity
489 completed trials (76% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.6%
42 terminated out of 640 trials
92.1%
+5.6% vs benchmark
25%
163 trials in Phase 3/4
26%
126 of 489 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 489 completed trials
Clinical Trials (640)
Zn Supplementation in HIV Immunological Non Responders
Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa
Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
Auto-immunity and Pulmonary Arterial Hypertension
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults
Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study
#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.
UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children
Baricitinib Curative Repression of HIV-1
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients